Efficacy of Second-Line Treatments in Lung and Extrapulmonary Neuroendocrine Carcinomas
Abstract views: 46
/ 
PDF downloads: 27
DOI:
https://doi.org/10.5281/zenodo.8404432Keywords:
Neuroendocrine tumors, Neuroendocrine carcinoma, Cisplatin-etoposide therapy, Second-line treatment, Ki-67 indexAbstract
Objective: The objective of this study was to explore the efficacy of second-line treatments, given the ambiguity surrounding subsequent treatments due to rapid disease progression and patient scarcity.
Materials & Methods: A retrospective study was conducted at the XXXX City Training and Research Hospital Medical Oncology Outpatient Clinic from 2017 to 2021, encompassing 991 patients diagnosed with lung cancer and NEC. Data from 304 patients, specifically diagnosed with NEC/Small-cell lung cancer, were analyzed. All patients underwent cisplatin-etoposide as their first-line treatment, with 35 of these receiving a second-line treatment.
Results: Of the analyzed patients, 91 were diagnosed with lung-derived-NEC and 35 with extrapulmonary-NEC. The median progression-free survival (PFS) post the first-line treatment was 7.4 months. A total of 35 patients received second-line chemotherapy. The median PFS2 was 5.1 months and 6.6 months in patients who received irinotecan-based chemotherapy and cisplatin-etoposide therapy, respectively(p:0.86). There was no significant difference between patients with lung-derived-NEC and patients with extrapulmonary-NEC in PFS2 or OS values.
Conclusion: The study underscores the lack of a standardized second-line treatment for small-cell lung cancer. However, data suggests that cisplatin-etoposide therapy might be effective as a second-line treatment, especially for patients relapsing after more than six months post the initial treatment. The outcomes align with other research, indicating a decline in overall survival as the Ki-67 index value increases
References
de M Rêgo, J. F., Salles Scortegagna de Medeiros, R., Braghiroli, M. I., Galvão, B., Evangelista Bezerra Neto, J., Ramella Munhoz, R., … Riechelmann, R. P. (2017). Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer.
Ecancermedicalscience, 11. https://doi.org/10.3332/ecancer.2017.767 Nöroendokrin tümörler, Nöroendokrin karsinom, Sisplatin-etoposid tedavisi, İkinci basamak tedavi, Ki-67 indeksi
Garcia-Carbonero, R., Sorbye, H., Baudin, E., Raymond, E., Wiedenmann, B., Niederle, B., … all other Vienna Consensus Conference participants. (2016). ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology, 103(2), 186–194. https://doi.org/10.1159/000443172
Hanna, N., Bunn, P. A., Langer, C., Einhorn, L., Guthrie, T., Beck, T., … Sandler, A. (2006). Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer. Journal of Clinical Oncology, 24(13), 2038–2043. https://doi.org/10.1200/JCO.2005.04.8595
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., … Liu, S. V. (2018). First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. New England Journal of Medicine, 379(23), 2220–2229.
https://doi.org/10.1056/NEJMoa1809064
Klöppel, G., Heitz, P. U., Capella, C., & Solcia, E. (1996). Pathology and Nomenclature of Human Gastrointestinal Neuroendocrine (Carcinoid) Tumors and Related Lesions. World Journal of Surgery, 20(2), 132–141. https://doi.org/10.1007/s002689900021
La Rosa, S., & Uccella, S. (2020). Classification of neuroendocrine neoplasms: Lights and shadows. Reviews in Endocrine and Metabolic Disorders. https://doi.org/10.1007/s11154-020-09612-2
Pujol, J.-L., Lavole, A., Quoix, E., Molinier, O., Souquet, P.-J., Barlesi, F., … Raspaud, C. (2015). Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: Results from the IFCT-0802 trial. Annals of Oncology, 26(5), 908–914. https://doi.org/10.1093/annonc/mdv065
Ramella Munhoz, R., de Mendonça Rego, J. F., de Celis Ferrari, A. R., Ignez Braghiroli, M., Mendonça Bariani, G., Marcelo Hoff, P., … Riechelmann, R. (2013). Combination of Irinotecan and a Platinum Agent for Poorly Differentiated Neuroendocrine Carcinomas. Rare
Tumors, 5(3), 135–139. https://doi.org/10.4081/rt.2013.e39
Sorbye, H., Welin, S., Langer, S. W., Vestermark, L. W., Holt, N., Osterlund, P., … Knigge, U. (2013). Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Annals of Oncology, 24(1), 152–160. https://doi.org/10.1093/annonc/mds276
Strosberg, J. R., Coppola, D., Klimstra, D. S., Phan, A. T., Kulke, M. H., Wiseman, G. A., & Kvols, L. K. (2010). The NANETS Consensus Guidelines for the Diagnosis and Management of Poorly Differentiated (High-Grade) Extrapulmonary Neuroendocrine Carcinomas.
Pancreas, 39(6), 799–800. https://doi.org/10.1097/MPA.0b013e3181ebb56f
Thomas, K. E. H., Voros, B. A., Boudreaux, J. P., Thiagarajan, R., Woltering, E. A., & Ramirez, R. A. (2019). Current Treatment Options in
Gastroenteropancreatic Neuroendocrine Carcinoma. The Oncologist, 24(8), 1076–1088. https://doi.org/10.1634/theoncologist.2018-0604
Walenkamp, A. M. E., Sonke, G. S., & Sleijfer, D. T. (2009). Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treatment Reviews, 35(3), 228–236. https://doi.org/10.1016/j.ctrv.2008.10.007
Yamaguchi, T., Machida, N., Morizane, C., Kasuga, A., Takahashi, H., Sudo, K., … Okusaka, T. (2014). Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Science, 105(9), 1176–1181. https://doi.org/10.1111/cas.12473
Zhang, C., Duan, J., He, Z., Yang, L., Yang, S., Zhang, Z., … Wang, J. (2021). The benefits of etoposide capsules as maintenance therapy for patients with extensive-stage small cell lung cancer: A prospective two-stage, two-center study. Journal of Thoracic Disease, 13(1), 343–352. https://doi.org/10.21037/jtd-21-106
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 GEVHER NESIBE JOURNAL OF MEDICAL AND HEALTH SCIENCES
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The journal is licensed under a 